

# Macopharma Press Release

October 6, 2020

## **Efficacious clinical application of convalescent plasma secured with the THERAFLEX MB-Plasma technology to treat pediatric COVID-19**

The successful SARS-CoV-2 elimination after convalescent plasma transfusion in a pediatric patient who was previously unresponsive to other conventional treatments was recently reported.<sup>1</sup>

One unit (200 ml) of convalescent plasma collected and treated in the Regional Blood Donor Centre in Poznań, Poland, with the THERAFLEX MB-Plasma system, designed and commercialized by Macopharma and a proven SARS-CoV-2 titer of 1:700, was sufficient to eliminate the virus.

The patient showed no improvement with previous conventional treatment for 5 weeks consecutively with IVIG, azithromycin 10, lopinavir-ritonavir, methylprednisolone and dexamethasone.

This case report showed that the THERAFLEX MB-Plasma procedure that is applied to the convalescent plasma preserved the functionality of the antibodies within the plasma of the donor. Moreover, no adverse events were observed.

### **About THERAFLEX MB-Plasma**

The THERAFLEX MB-Plasma System has a Class III CE Mark (available for sale in countries where the CE mark is accepted) and is not currently available for sale in the United States. It is a user-friendly in-house treatment for single units of plasma. The GMP-conforming procedure is adapted for the inactivation of FFP from aphaeresis or whole blood plasma. The MB plasma system uses a combination of a membrane filter Plasmaflex PLAS4, (which removes residual leucocytes, red cells, platelets and aggregates, intra-cellular viruses and minimises the number of microvesicles and microparticles), a dry Methylene Blue pill, visible light and a Blueflex Methylene Blue removal filter.

### **About the Regional Blood Donor Center in Poznań, Poland**

Regional Blood Donor Center in Poznań with the total number of over 100.000 donations in its main seat, 13 satellite branches and 4 mobile units for blood collection is one of the largest in Poland. It performs laboratory testing using highly specialized equipment for its purposes and other Regional Blood Centers in Poland (e.g. HBV, HCV, HIV NAT testing, B19, HAV, HEV). Furthermore, it is very active in the field of genetic laboratory testing – it performs donor-recipient testing for transplant patients (heart, lungs, kidneys); HLA typing and confirmatory testing; detects and identifies antibodies of transplant significance; coordinates bone marrow donor-recipient procedures and performs matching procedures of unrelated and haploidentical donors.

Regional Blood Donor Center in Poznań constantly searches for new ways to optimize work and most of all to increase the safety of blood and its components e.g. by introducing the inactivation of plasma using the THERAFLEX MB-Plasma system in its routine work for plasma released to the hospitals, including the convalescent plasma for the SARS-CoV-2 patients.

## About Macopharma

Macopharma creates quality innovative blood products and bio-sourced therapies for patients. We are dedicated to raising the standards of care by relying on close relationships with our suppliers and users, and questioning ourselves constantly to become the world's most trusted healthcare partner.

Maintaining confidence by committing to a comprehensive business continuity plan and a sustainable development while fighting against all forms of discrimination are part of our values. We also believe that working collaboratively is a key element to meet challenges and imagine tomorrow's products and services.

As yesterday and today, we will continue to support life in the future.

1. Figlerowicz M, Mania A, Lubarski K, Lewandowska Z, Sluzewski W, Derwich K, Wachowiak J, Mazur-Melewska K. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia. *Transfus Apher Sci*, <https://doi.org/10.1016/j.transci.2020.102866>.